Bernard A. Fox: We need to do more for every patient fighting cancer
Bernard A. Fox, Co-Founder, President, and CEO of UbiVac, shared on LinkedIn:
“A friend of mine underwent surgery for recurrent GBM/Glioblastoma (brain cancer) at University of Michigan Medical School this past Wednesday—he’s now out of the ICU and talking. That’s incredible news, but it’s not enough. We need to do more—for him and for every patient fighting cancer.
That same day, a major medical journal published a study by Toni Choueiri and colleagues showing that combination immunotherapy with a cancer vaccine helped prevent kidney cancer recurrence (PMID: 39910301).
Similar findings have been reported in melanoma (PMID: 38246194) and pancreatic cancer (PMID: 37165196), where vaccine-based combination therapies reduced the risk of relapse. Immunotherapy is proving to be a game-changer, offering hope to patients—but progress isn’t moving fast enough for those like my friend with GBM.
Cancer patients are in the fight of their lives, and like many bench-to-bedside translational Cancer Centers worldwide, my colleagues and I at UbiVac, Earle A. Chiles Research Institute and Providence Cancer Institute are pushing boundaries to develop innovative treatments in the race to Finish Cancer. GBM and other brain cancers remain areas of high unmet need, where combination immunotherapy—including vaccines—could make a difference.
UbiVac’s DPV-001, which has tripled response rates in patients with advanced headandneck (HNSCC) cancer, contains cancer’s Dark Matter, alternative cancer neoantigens (PMID: 33852826 , https://www.ubivac.com/) , and was designed to target a wide range of solid tumors, including GBM. We are grateful to Incyte for supporting our current clinical trial in HNSCC and are seeking partners to help expand this promising treatment strategy to other cancers in urgent need of better options and trials that offer hope for more patients with cancer.
I am incredibly proud of the work we do, but even more so of the amazing people in this video who are facing cancer head-on. That’s why I’m sharing it again.
Thanks as well to my colleagues, past and present, who continue to make a difference in this fight to FINISH CANCER.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023